Expertise in
8
conditions

Dr. Cathy Eng

Gastroenterology
Vanderbilt-Ingram Cancer Center
2220 Pierce Ave, 
Nashville, TN 
Offers Telehealth
Expertise in
8
conditions
Vanderbilt-Ingram Cancer Center
2220 Pierce Ave, 
Nashville, TN 

Overview

Cathy Eng is a Gastroenterologist in Nashville, Tennessee. Dr. Eng is highly rated in 8 conditions, according to our data. Her top areas of expertise are Anal Cancer, Colorectal Cancer, Appendix Cancer, Hepato-Pancreato-Biliary Surgery, and Hepatectomy.

Her clinical research consists of co-authoring 302 peer reviewed articles and participating in 11 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Gastroenterology

Licenses

Internal Medicine in TN

Hospital Affiliations

Vanderbilt University Medical Center

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Alliant Health
  • HMO
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Oscar
  • EPO
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
View 7 Less Insurance Carriers -

Locations

Vanderbilt-Ingram Cancer Center
2220 Pierce Ave, Nashville, TN 37232

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

A Randomized Phase III Study of Immune Checkpoint Inhibition With Chemotherapy in Treatment-Naive Metastatic Anal Cancer Patients
A Randomized Phase III Study of Immune Checkpoint Inhibition With Chemotherapy in Treatment-Naive Metastatic Anal Cancer Patients
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2026
Intervention Type: Biological, Drug
Study Drugs: Carboplatin, Nivolumab, Paclitaxel
Study Phase: Phase 3
A Randomized Phase III Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer
A Randomized Phase III Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2026
Intervention Type: Procedure, Biological, Other
Study Drug: Nivolumab
Study Phase: Phase 3
A Randomized Phase II Study of De-Intensified ChemoRadiation for Early-Stage Anal Squamous Cell Carcinoma (DECREASE)
A Randomized Phase II Study of De-Intensified ChemoRadiation for Early-Stage Anal Squamous Cell Carcinoma (DECREASE)
Enrollment Status: Active_not_recruiting
Publish Date: January 26, 2026
Intervention Type: Other, Procedure, Drug, Radiation
Study Drugs: Capecitabine, Fluorouracil, Mitomycin
Study Phase: Phase 2
A Phase 1b/2, Open-Label, Randomized Platform Study Evaluating The Efficacy and Safety of AB928 Based Treatment Combinations in Patients With Metastatic Colorectal Cancer
A Phase 1b/2, Open-Label, Randomized Platform Study Evaluating The Efficacy and Safety of AB928 Based Treatment Combinations in Patients With Metastatic Colorectal Cancer
Enrollment Status: Completed
Publish Date: October 20, 2025
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase 2/3, Randomized, Open-Label Study of Maintenance GRT-C901/GRT-R902, A Neoantigen Vaccine, in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer
A Phase 2/3, Randomized, Open-Label Study of Maintenance GRT-C901/GRT-R902, A Neoantigen Vaccine, in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: May 16, 2025
Intervention Type: Drug
Study Phase: Phase 2/Phase 3
A Multi-Institutional Phase 2 Study of Nivolumab or Nivolumab in Combination With Ipilimumab in Refractory Metastatic Squamous Cell Carcinoma of the Anal Canal
A Multi-Institutional Phase 2 Study of Nivolumab or Nivolumab in Combination With Ipilimumab in Refractory Metastatic Squamous Cell Carcinoma of the Anal Canal
Enrollment Status: Active_not_recruiting
Publish Date: April 29, 2025
Intervention Type: Procedure, Biological
Study Drugs: Ipilimumab, Nivolumab
Study Phase: Phase 2
A Global Multicenter Randomized Placebo-Controlled Phase 3 Trial To Compare The Efficacy And Safety Of Fruquintinib Plus Best Supportive Care To Placebo Plus Best Supportive Care In Patients With Refractory Metastatic Colorectal Cancer
A Global Multicenter Randomized Placebo-Controlled Phase 3 Trial To Compare The Efficacy And Safety Of Fruquintinib Plus Best Supportive Care To Placebo Plus Best Supportive Care In Patients With Refractory Metastatic Colorectal Cancer
Enrollment Status: Completed
Publish Date: April 04, 2025
Intervention Type: Drug
Study Drug: Fruquintinib
Study Phase: Phase 3
A Multi-Center, Open-Label, Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anticancer Activity of Fruquintinib in Patients With Advanced Solid Tumors
A Multi-Center, Open-Label, Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anticancer Activity of Fruquintinib in Patients With Advanced Solid Tumors
Enrollment Status: Completed
Publish Date: September 25, 2024
Intervention Type: Drug
Study Drug: Fruquintinib
Study Phase: Phase 1
InterAACT - An International Multicentre Open Label Randomised Phase II Advanced Anal Cancer Trial Comparing Cisplatin Plus 5-Fluorouracil Versus Carboplatin Plus Weekly Paclitaxel in Patients With Inoperable Locally Recurrent or Metastatic Disease
InterAACT - An International Multicentre Open Label Randomised Phase II Advanced Anal Cancer Trial Comparing Cisplatin Plus 5-Fluorouracil Versus Carboplatin Plus Weekly Paclitaxel in Patients With Inoperable Locally Recurrent or Metastatic Disease
Enrollment Status: Unknown
Publish Date: June 22, 2023
Intervention Type: Other, Drug
Study Drugs: Capecitabine, Carboplatin, Cisplatin, 5-Fluorouracil, Paclitaxel
Study Phase: Phase 2
A Phase 1, Multicenter, Open-Label, Dose Escalation and Dose Expansion Study of SQZ-PBMC-HPV as Monotherapy and in Combination With Atezolizumab or Other Immune Checkpoint Inhibitors in HLA-A*02+ Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors
A Phase 1, Multicenter, Open-Label, Dose Escalation and Dose Expansion Study of SQZ-PBMC-HPV as Monotherapy and in Combination With Atezolizumab or Other Immune Checkpoint Inhibitors in HLA-A*02+ Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors
Enrollment Status: Completed
Publish Date: April 14, 2023
Intervention Type: Drug, Biological
Study Drugs: SQZ-PBMC-HPV, Atezolizumab, Ipilimumab, Nivolumab
Study Phase: Phase 1
View 9 Less Clinical Trials

302 Total Publications

NCI9673 (Part B): ETCTN Randomized Phase II Study of Nivolumab With or Without Ipilimumab in Refractory, Metastatic Squamous Cell Carcinoma of the Anal Canal.
NCI9673 (Part B): ETCTN Randomized Phase II Study of Nivolumab With or Without Ipilimumab in Refractory, Metastatic Squamous Cell Carcinoma of the Anal Canal.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: January 07, 2026
Similar Doctors
Expertise in
14
conditions
Dr. Michael Vaezi
Gastroenterology
Expertise in
14
conditions
Dr. Michael Vaezi
Gastroenterology

Office

1301 Medical Center Dr Ste 1660, 
Nashville, TN 
 (0.1 miles away)
615-322-7427
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Michael Vaezi is a Gastroenterologist in Nashville, Tennessee. Dr. Vaezi is highly rated in 14 conditions, according to our data. His top areas of expertise are Gastroesophageal Reflux Disease (GERD), Esophagitis, Achalasia, Heartburn, and Endoscopy.

Expertise in
11
conditions
Dr. David Schwartz
Gastroenterology
Expertise in
11
conditions
Dr. David Schwartz
Gastroenterology

Office

719 Thompson Ln Ste 20500, 
Nashville, TN 
 (2.7 miles away)
615-322-0128
Languages Spoken:
English
See accepted insurances
Offers Telehealth

David Schwartz is a Gastroenterologist in Nashville, Tennessee. Dr. Schwartz is highly rated in 11 conditions, according to our data. His top areas of expertise are Crohn's Disease, Pulmonary Fibrosis, Viral Gastroenteritis, Endoscopy, and Colonoscopy.

Expertise in
14
conditions
Dr. Jordan Berlin
Gastroenterology
Expertise in
14
conditions
Dr. Jordan Berlin
Gastroenterology

Vanderbilt-Ingram Cancer Center

2220 Pierce Ave, 
Nashville, TN 
 (0.1 miles away)
615-322-5000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Jordan Berlin is a Gastroenterologist in Nashville, Tennessee. Dr. Berlin is highly rated in 14 conditions, according to our data. His top areas of expertise are Neuroendocrine Tumor, Pancreatic Cancer, Colorectal Cancer, Pancreaticoduodenectomy, and Pancreatectomy.

Frequently Asked Questions about Dr. Cathy Eng

How do I make an appointment with Dr. Cathy Eng?

You can book an appointment with Dr. Cathy Eng by calling their office at 615-322-5000. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Cathy Eng a top-rated expert for Anal Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Cathy Eng is classified as an Elite expert for Anal Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Cathy Eng specialize in?

While Dr. Cathy Eng is a Gastroenterology, they have specific expertise in Anal Cancer, Colorectal Cancer, and Appendix Cancer. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Gastroenterology.

Does Dr. Cathy Eng participate in research or clinical trials?

Yes. Dr. Cathy Eng has published 302 articles and abstracts on conditions like Anal Cancer. You can view a list of Dr. Cathy Eng's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Cathy Eng accept my insurance?

Dr. Cathy Eng accepts most major insurance plans, including Aetna and Alliant Health. We recommend calling the office directly at 615-322-5000 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Eng's expertise for a condition
ConditionClose
View All 14 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile